[ Eloxx raises $24M in Series C ]

Eloxx has raised $24 million in Series C funding.

Founded in 2013, Eloxx is a Pontifax portfolio company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others.

This financing enables the company  to initiate multiple clinical studies for EL-02, Eloxx’s lead compound.

Funding  Series C
Founded  2013
Country  Israel
City  Herzliya
Founder / CEO  Silvia Noiman
Deal Size  $24M
Investors  Pontifax
 GF Securities
 Quark Venture
Previous Investors  /